TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 29849487

Group type: EXPERIMENTAL
Intervention: Progressive resistance exercise (n = 49)
Number of subjects: 125

Group type: EXPERIMENTAL
Intervention: Relaxation therapy (n = 43)
Number of subjects: 125

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 125
Study: 27470121

Group type: EXPERIMENTAL
Intervention: Experimental group (N = 103)
Number of subjects: 219

Group type: COMPARATOR
Intervention: Control group (N = 116)
Number of subjects: 219
Study: 24272364

Group type: EXPERIMENTAL
Intervention: Cytology triage at atypical squamous cells of undetermined significance threshold
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Visual inspection with acetic acid (VIA) triage
Number of subjects: 0
Study: 22976384

Group type: EXPERIMENTAL
Intervention: Virtual reality balance training (VRBT) for 30 min a day, 3 times a week for 6 weeks
Number of subjects: 22

Group type: COMPARATOR
Intervention: Control group (standard rehabilitation program)
Number of subjects: 22
Study: 19282749

Group type: EXPERIMENTAL
Intervention: Pulsatile perfusion (PP)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Nonpulsatile perfusion (NP)
Number of subjects: 24
Study: 17768472

Group type: EXPERIMENTAL
Intervention: Topical 10% zinc sulphate solution
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Topical 5% zinc sulphate solution
Number of subjects: 100

Group type: COMPARATOR
Intervention: Distilled water (control)
Number of subjects: 100
Study: 15514406

Group type: EXPERIMENTAL
Intervention: Citalopram, 10-40 mg/day
Number of subjects: 174

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 174

Group type: EXPERIMENTAL
Intervention: Citalopram
Number of subjects: 174
Study: 11580079

Group type: EXPERIMENTAL
Intervention: Alendronate (5 mg/day for 2 years and then 10 mg/day for 1 year)
Number of subjects: 2027
Study: 9694049

Group type: EXPERIMENTAL
Intervention: Patients with factor V Leiden mutation
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Patients without factor V Leiden mutation
Number of subjects: 34

Group type: COMPARATOR
Intervention: Healthy control subjects
Number of subjects: 34
Study: 7633170

Group type: EXPERIMENTAL
Intervention: Ovum pickup at 36 hr after hCG injection (group B)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Ovum pickup at 35 hr after hCG injection (group A)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Ovum pickup at 37 hr after hCG injection (group C)
Number of subjects: 90
Study: 3129780

Group type: EXPERIMENTAL
Intervention: Phenoxymethylpenicillin for 5 days
Number of subjects: 216

Group type: EXPERIMENTAL
Intervention: Phenoxymethylpenicillin for 10 days
Number of subjects: 216

Group type: EXPERIMENTAL
Intervention: Cefadroxil for 10 days
Number of subjects: 216
Study: 29183910

Group type: EXPERIMENTAL
Intervention: Intensifying treatments to three oral agents or insulin regimens
Number of subjects: 5813

Group type: EXPERIMENTAL
Intervention: Insulin alone use
Number of subjects: 5813

Group type: EXPERIMENTAL
Intervention: Treatment satisfaction (patient-reported)
Number of subjects: 5813

Group type: EXPERIMENTAL
Intervention: Audit of Diabetes‐Dependent Quality of Life (ADDQoL)
Number of subjects: 5813

Group type: EXPERIMENTAL
Intervention: Hypoglycemia Fear Survey‐II worry subscale
Number of subjects: 5813

Group type: COMPARATOR
Intervention: No treatment
Number of subjects: 5813
Study: 26414990

Group type: EXPERIMENTAL
Intervention: Milnacipran (100 mg/d)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study: 24210533

Group type: EXPERIMENTAL
Intervention: Motivational interviewing (MI)
Number of subjects: 165

Group type: COMPARATOR
Intervention: Brief advice (BA)
Number of subjects: 165

Group type: COMPARATOR
Intervention: Brief advice (BA) with nicotine replacement (NRT)
Number of subjects: 165

Group type: EXPERIMENTAL
Intervention: Motivational interviewing (MI) with nicotine replacement (NRT)
Number of subjects: 165
Study: 23945386

Group type: EXPERIMENTAL
Intervention: Overexpression of WT1 in H1568 and H1650 NSCLC cell lines
Number of subjects: 159

Group type: EXPERIMENTAL
Intervention: Knockdown of WT1 in H1568 and H1650 NSCLC cell lines
Number of subjects: 159

Group type: EXPERIMENTAL
Intervention: WT1 mRNA levels
Number of subjects: 159

Group type: EXPERIMENTAL
Intervention: Clinical correlation of WT1 expression
Number of subjects: 159
Study: 20843375

Group type: EXPERIMENTAL
Intervention: Neutral pH, low GDP dialysis solution (Balance)
Number of subjects: 185

Group type: COMPARATOR
Intervention: Conventional dialysis solution (Stay.safe)
Number of subjects: 185
Study: 18993156

Group type: EXPERIMENTAL
Intervention: 16-week group-based aerobic high-intensity interval training model twice weekly for 65 to 80 minutes/day (n = 40)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Standard care (control group, n = 40)
Number of subjects: 80
Study: 17132385

Group type: EXPERIMENTAL
Intervention: Standardised advice and a tapering off schedule with biweekly follow‐up visits (n = 73)
Number of subjects: 139

Group type: COMPARATOR
Intervention: Routine clinical practice (n = 66)
Number of subjects: 139
Study: 12932090

Group type: EXPERIMENTAL
Intervention: Five-day course of artesunate (Group A5)
Number of subjects: 801

Group type: EXPERIMENTAL
Intervention: Seven-day course of artesunate (Group A7)
Number of subjects: 801

Group type: EXPERIMENTAL
Intervention: Five-day course of artesunate plus a 14-day course of high-dose primaquine (0.6 mg/kg, maximum dose = 30 mg) (Group A5 + P)
Number of subjects: 801

Group type: EXPERIMENTAL
Intervention: Seven-day course of artesunate plus a 14-day course of high-dose primaquine (Group A7 + P)
Number of subjects: 801

Group type: EXPERIMENTAL
Intervention: High-dose primaquine (0.6 mg/kg of base a day)
Number of subjects: 801
Study: 14747668

Group type: EXPERIMENTAL
Intervention: Diet providing an ample protein intake (1.67 g. kg fat-free mass(‐1). d(‐1))
Number of subjects: 14

Group type: COMPARATOR
Intervention: Diet approximating the mean minimum adult protein requirement (0.71 g. kg fat-free mass(‐1). d(‐1))
Number of subjects: 14
Study: 10203120

Group type: EXPERIMENTAL
Intervention: Simulated Presence
Number of subjects: 54

Group type: COMPARATOR
Intervention: Usual Care
Number of subjects: 54

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 54
Study: 7760775

Group type: EXPERIMENTAL
Intervention: Elemental mercury exposure (mean urinary Hg = 36 micrograms/l)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Unexposed dentists (control group)
Number of subjects: 39
Study: 1970265

Group type: EXPERIMENTAL
Intervention: Carvedilol (25 mg, single oral dose)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo (control)
Number of subjects: 0
Study: 394870

Group type: EXPERIMENTAL
Intervention: CFP (cyclophosphamide, 5-fluorouracil, and prednisone)
Number of subjects: 71

Group type: COMPARATOR
Intervention: CFP + MER (methanol-extracted residue of Bacillus Calmette-Guerin)
Number of subjects: 71
Study: 28923093

Group type: EXPERIMENTAL
Intervention: Improved sanitation intervention
Number of subjects: 720

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 720
Study: 26420261

Group type: EXPERIMENTAL
Intervention: Xpert MTB/RIF assay
Number of subjects: 130

Group type: EXPERIMENTAL
Intervention: Combination of GA and IS samples
Number of subjects: 130

Group type: COMPARATOR
Intervention: Smear microscopy
Number of subjects: 130

Group type: COMPARATOR
Intervention: BACTEC-MGIT culture
Number of subjects: 130

Group type: EXPERIMENTAL
Intervention: GA samples
Number of subjects: 130

Group type: EXPERIMENTAL
Intervention: IS samples
Number of subjects: 130
Study: 23566774

Group type: EXPERIMENTAL
Intervention: Naltrexone
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Naltrexone without CBI
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo naltrexone
Number of subjects: 0
Study: 21123958

Group type: EXPERIMENTAL
Intervention: Coping training program with 14 weekly two-hour sessions
Number of subjects: 396

Group type: COMPARATOR
Intervention: Normal work (control group)
Number of subjects: 396
Study: 19137459

Group type: EXPERIMENTAL
Intervention: Intravesical dimethyl sulfoxide (DMSO)
Number of subjects: 151

Group type: COMPARATOR
Intervention: Bacille Calmette-Guerin (BCG)
Number of subjects: 151

Group type: EXPERIMENTAL
Intervention: Oral cyclosporine A (CyA)
Number of subjects: 151

Group type: COMPARATOR
Intervention: Pentosan polysulfate sodium (PPS)
Number of subjects: 151
Study: 17254598

Group type: EXPERIMENTAL
Intervention: Native QRS width in second-degree AV block group
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Native QRS width in total AV block group
Number of subjects: 50
Study: 15126758

Group type: EXPERIMENTAL
Intervention: Medical treatment (3 month course of a macrolide antibiotic, douche, and topical steroid)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Surgical treatment
Number of subjects: 90
Study: 11787915

Group type: EXPERIMENTAL
Intervention: Oral misoprostol (500 microg)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Intravenous Syntocinon (10 iu)
Number of subjects: 40
Study: 9470910

Group type: EXPERIMENTAL
Intervention: Gluconolactone (GLU)
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Tartaric acid (TA)
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Glycolic acid (GA)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Vehicle (VE)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Untreated control (UNT)
Number of subjects: 11
Study: 8196432

Group type: EXPERIMENTAL
Intervention: Primary functional treatment without external or internal stabilization
Number of subjects: 70
Study: 3069522

Group type: EXPERIMENTAL
Intervention: Low molecular weight heparin
Number of subjects: 80

Group type: COMPARATOR
Intervention: Calcium heparin
Number of subjects: 80
Study: 31728714

Group type: EXPERIMENTAL
Intervention: Itraconazole (200 mg/day for 11 days)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Lorlatinib alone (50 mg, 75 mg, 100 mg)
Number of subjects: 16
Study: 30816025

Group type: EXPERIMENTAL
Intervention: High flow nasal cannula (HFNC)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Nasal continuous positive airway pressure (NCPAP)
Number of subjects: 30
Study: 28525543

Group type: EXPERIMENTAL
Intervention: Fructan (12 g/d)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Glucose placebo (12 g/d)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Galacto-oligosaccharides (GOS, 6 g/d)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Sorbitol (6 g/d)
Number of subjects: 32
Study: 26204908

Group type: EXPERIMENTAL
Intervention: Self-reported physical activity
Number of subjects: 4282

Group type: EXPERIMENTAL
Intervention: Self-reported walking activity
Number of subjects: 4282

Group type: COMPARATOR
Intervention: Objectively measured ambulatory activity
Number of subjects: 4282

Group type: COMPARATOR
Intervention: Time spent in MVPA (objectively measured)
Number of subjects: 4282

Group type: COMPARATOR
Intervention: Self-reported MVPA
Number of subjects: 4282
Study: 23945113

Group type: EXPERIMENTAL
Intervention: VAC therapy with mobile VAC Freedom device
Number of subjects: 19

Group type: COMPARATOR
Intervention: Standard wound dressing after simple excision
Number of subjects: 19
Study: 21808761

Group type: EXPERIMENTAL
Intervention: Human dermis graft (HDG)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Autogenous connective tissue graft (ACT)
Number of subjects: 42
Study: 19299839

Group type: EXPERIMENTAL
Intervention: Feldenkrais intervention (twice‐weekly group classes over 8 weeks)
Number of subjects: 55

Group type: COMPARATOR
Intervention: Control group (usual activity)
Number of subjects: 55
Study: 17520889

Group type: EXPERIMENTAL
Intervention: Rabeprazole
Number of subjects: 0

Group type: COMPARATOR
Intervention: Omeprazole
Number of subjects: 0
Study: 15355387

Group type: EXPERIMENTAL
Intervention: Dark coronal discoloration
Number of subjects: 97
Study: 11772893

Group type: EXPERIMENTAL
Intervention: Computer-generated personalized report intervention
Number of subjects: 150

Group type: COMPARATOR
Intervention: Standard care (control)
Number of subjects: 150

Group type: COMPARATOR
Intervention: Control group (among patients experiencing a decline)
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Intervention group (among patients experiencing a decline)
Number of subjects: 150
Study: 9843010

Group type: EXPERIMENTAL
Intervention: Class I compression stockings (18 to 26 mm Hg)
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Class II compression stockings (26 to 36 mm Hg)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Class I and II compression stockings
Number of subjects: 11
Study: 8582812

Group type: EXPERIMENTAL
Intervention: Noncontact Therapeutic Touch
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 2772103

Group type: EXPERIMENTAL
Intervention: Caffeine (125 mg) followed by a second dose of caffeine
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 73429

Group type: EXPERIMENTAL
Intervention: Skin tests with food extracts (1:20 w/v concentration)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Double-blind food challenge
Number of subjects: 0

Group type: COMPARATOR
Intervention: In vitro release of histamine from leucocytes
Number of subjects: 0
Study: 30963460

Group type: EXPERIMENTAL
Intervention: Cricoid-mental distance-based group
Number of subjects: 74

Group type: COMPARATOR
Intervention: Weight-based group
Number of subjects: 74
Study: 28678952

Group type: EXPERIMENTAL
Intervention: 0.25% sodium hypochlorite (S1)
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: 0.5% sodium hypochlorite (S2)
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: 10% R. communis (S3)
Number of subjects: 64

Group type: COMPARATOR
Intervention: Control (Saline, S4)
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: 0.25% sodium hypochlorite (S1) and 0.5% sodium hypochlorite (S2)
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Patient satisfaction
Number of subjects: 64
Study: 25196702

Group type: EXPERIMENTAL
Intervention: Bosutinib 500 mg/d
Number of subjects: 502

Group type: COMPARATOR
Intervention: Imatinib 400 mg/d
Number of subjects: 502
Study: 23623755

Group type: EXPERIMENTAL
Intervention: Ramipril/HCTZ fixed-dose combination (5/25 mg/d) - Group A (test formulation)
Number of subjects: 102

Group type: COMPARATOR
Intervention: Ramipril/HCTZ fixed-dose combination (5/25 mg/d) - Group B (reference formulation)
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Both groups (A and B)
Number of subjects: 102
Study: 21527231

Group type: EXPERIMENTAL
Intervention: Diaphragmatic breathing and pelvic floor muscles (PFM) retraining in group A
Number of subjects: 86

Group type: COMPARATOR
Intervention: Standard urotherapy in group B
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: Both groups received treatment for constipation and recurrent urinary tract infections (UTIs)
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: Both groups received uroflowmetry with pelvic floor electromyography and ultrasound residual urine volumes
Number of subjects: 86
Study: 18384519

Group type: EXPERIMENTAL
Intervention: 8-week treatment regimen of peginterferon and ribavirin
Number of subjects: 61

Group type: COMPARATOR
Intervention: 24-week treatment regimen of peginterferon and ribavirin
Number of subjects: 61
Study: 16996596

Group type: EXPERIMENTAL
Intervention: Subthreshold grid laser treatment (SGLT)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Threshold grid laser treatment (TGLT)
Number of subjects: 36
Study: 14966078

Group type: EXPERIMENTAL
Intervention: General leaflet
Number of subjects: 636

Group type: EXPERIMENTAL
Intervention: Depression leaflet
Number of subjects: 636

Group type: COMPARATOR
Intervention: Neither leaflet
Number of subjects: 636
Study: 10896845

Group type: EXPERIMENTAL
Intervention: Free nicotine patches plus proactive telephone peer support
Number of subjects: 214

Group type: COMPARATOR
Intervention: Free nicotine patches only
Number of subjects: 214
Study: 9084100

Group type: EXPERIMENTAL
Intervention: Left hemiparetic patients
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Right hemiparetic patients
Number of subjects: 15

Group type: COMPARATOR
Intervention: Healthy control subjects
Number of subjects: 15
Study: 8451961

Group type: EXPERIMENTAL
Intervention: Active ankle movement with weight bearing in an orthosis
Number of subjects: 40

Group type: COMPARATOR
Intervention: Active ankle movement without weight bearing using a dorsal splint
Number of subjects: 40
Study: 3090723

Group type: EXPERIMENTAL
Intervention: Growth Hormone (10 mg daily)
Number of subjects: 4

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4
Study: 31103640

Group type: EXPERIMENTAL
Intervention: Language control during cooperative picture-naming
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Inhibition of cross‐language interference and interpersonal interference
Number of subjects: 13
Study: 29703633

Group type: EXPERIMENTAL
Intervention: Oral iron (50 mg of sodium ferrous citrate daily; oral group, n = 29)
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Intravenous iron (40 mg of saccharated ferric oxide weekly; IV group, n = 32)
Number of subjects: 61

Group type: COMPARATOR
Intervention: Both groups (oral and IV iron)
Number of subjects: 61
Study: 26187522

Group type: EXPERIMENTAL
Intervention: Physical exercise plus usual care
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Psycho-educational intervention plus usual care
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Physical exercise and psycho-educational plus usual care
Number of subjects: 60

Group type: COMPARATOR
Intervention: Usual care alone
Number of subjects: 60
Study: 24000053

Group type: EXPERIMENTAL
Intervention: PATH+ intervention (community-based care management by an advanced practice nurse, minimum of one visit/week for 12 months)
Number of subjects: 238
Study: 22917853

Group type: EXPERIMENTAL
Intervention: MAP0004 (3.0 mg, supratherapeutic dose)
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Moxifloxacin (400 mg)
Number of subjects: 54

Group type: COMPARATOR
Intervention: Placebo (inactive vehicle)
Number of subjects: 54
Study: 19825815

Group type: EXPERIMENTAL
Intervention: Paclitaxel plus carboplatin (TC)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Paclitaxel plus cisplatin (TP)
Number of subjects: 0
Study: 17828038

Group type: EXPERIMENTAL
Intervention: Combination therapy (200 mg of intravenous erythromycin twice daily + 10 mg of intravenous metoclopramide four times daily)
Number of subjects: 75

Group type: COMPARATOR
Intervention: Erythromycin alone (200 mg of intravenous erythromycin twice daily)
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Combination therapy
Number of subjects: 75

Group type: COMPARATOR
Intervention: Erythromycin alone
Number of subjects: 75
Study: 15142201

Group type: EXPERIMENTAL
Intervention: Intravenous lansoprazole in NaCl
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Intravenous lansoprazole in polyethylene glycol
Number of subjects: 65

Group type: COMPARATOR
Intervention: Per oral lansoprazole
Number of subjects: 65

Group type: COMPARATOR
Intervention: Intravenous placebo
Number of subjects: 65
Study: 11574346

Group type: EXPERIMENTAL
Intervention: Fentanyl
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Sufentanil
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Remifentanil
Number of subjects: 90
Study: 9757955

Group type: EXPERIMENTAL
Intervention: Intensive reminder system (mail and telephone reminders)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Scheduled appointment reminders only
Number of subjects: 0
Study: 8141443

Group type: EXPERIMENTAL
Intervention: S-(+)-ketamine
Number of subjects: 40

Group type: COMPARATOR
Intervention: Racemic ketamine
Number of subjects: 40
Study: 2899588

Group type: EXPERIMENTAL
Intervention: Cefuroxime 750 mg and piperacillin 4 g (3 doses)
Number of subjects: 53

Group type: COMPARATOR
Intervention: No prophylaxis
Number of subjects: 53
Study: 4895339

Group type: EXPERIMENTAL
Intervention: Methoxyflurane (0.35%) in air
Number of subjects: 50

Group type: COMPARATOR
Intervention: Nitrous oxide/oxygen (50%/50%)
Number of subjects: 50
Study: 31678231

Group type: EXPERIMENTAL
Intervention: Antibiotic treatment
Number of subjects: 90
Study: 29100829

Group type: EXPERIMENTAL
Intervention: ChronOS
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: ChronOS and autogenous bone graft in a 1:1 ratio
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Bio-Oss
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Bio-Oss and autogenous bone graft in a 1:1 ratio
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Autogenous bone graft alone
Number of subjects: 30
Study: 28414583

Group type: EXPERIMENTAL
Intervention: Varenicline and behavioral therapy
Number of subjects: 179
Study: 26377497

Group type: EXPERIMENTAL
Intervention: Hypnosis session (10-min presurgery)
Number of subjects: 64

Group type: COMPARATOR
Intervention: Control session (presurgery)
Number of subjects: 64
Study: 23153598

Group type: EXPERIMENTAL
Intervention: TKA with patellar eversion
Number of subjects: 72

Group type: COMPARATOR
Intervention: TKA without patellar eversion
Number of subjects: 72
Study: 21822144

Group type: EXPERIMENTAL
Intervention: Omeprazole 40 mg once daily for 5 days
Number of subjects: 0

Group type: COMPARATOR
Intervention: Rivaroxaban 20 mg single dose
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Rivaroxaban 20 mg single dose after 5 days of omeprazole
Number of subjects: 0
Study: 19060642

Group type: EXPERIMENTAL
Intervention: Patient-Centered Care (PCC)
Number of subjects: 116

Group type: COMPARATOR
Intervention: Usual Care (Control)
Number of subjects: 116
Study: 16219327

Group type: EXPERIMENTAL
Intervention: L-dopa
Number of subjects: 52

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 52
Study: 12667513

Group type: EXPERIMENTAL
Intervention: Cognitive behavioural therapy (CBT)
Number of subjects: 10
Study: 10670394

Group type: EXPERIMENTAL
Intervention: Lactose-free infant formula
Number of subjects: 137

Group type: COMPARATOR
Intervention: Lactose-containing infant formula
Number of subjects: 137
Study: 9147709

Group type: EXPERIMENTAL
Intervention: Acipimox 250 mg thrice daily
Number of subjects: 106

Group type: COMPARATOR
Intervention: Pravastatin 20 mg once daily
Number of subjects: 106
Study: 8365915

Group type: EXPERIMENTAL
Intervention: Psychological training program (part of a comprehensive rehabilitation program lasting over six months, consisting of four modules)
Number of subjects: 51

Group type: COMPARATOR
Intervention: Attention control group
Number of subjects: 51
Study: 3921380

Group type: EXPERIMENTAL
Intervention: Dazoxiben
Number of subjects: 2
Study: 30481333

Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral therapy for insomnia (CBTI)
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Sleep restriction therapy (SRT)
Number of subjects: 150

Group type: COMPARATOR
Intervention: Sleep hygiene education (SHE)
Number of subjects: 150